e-learning
resources
Munich 2014
Monday, 08.09.2014
New clinical evidence for asthma and COPD treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
A. D'Urzo, D. A. Mahler, C. Karakurum, H. Chen, R. Fogel, D. Banerji (Toronto, Canada; Hanover, East Hanover, United States Of America; Basel, Switzerland)
Source:
International Congress 2014 – New clinical evidence for asthma and COPD treatments
Session:
New clinical evidence for asthma and COPD treatments
Session type:
Thematic Poster Session
Number:
2418
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. D'Urzo, D. A. Mahler, C. Karakurum, H. Chen, R. Fogel, D. Banerji (Toronto, Canada; Hanover, East Hanover, United States Of America; Basel, Switzerland). QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study. Eur Respir J 2014; 44: Suppl. 58, 2418
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept